Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Long-acting antiretrovirals were the big news at CROI this year; now two of the most promising are joining forces.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
The HIV regimen failed only a few study participants.
AIDS United speaks with Deondre Moore about promoting U=U among African Americans via the “Owning HIV” campaign.
Survey findings from the “Owning HIV” campaign show the need for proactive education.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
This is according to a three-year study in which people switched from a stable HIV regimen to Delstrigo.
None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.
A mid-stage trial showed the combo suppressed HIV, was well tolerated and resulted in a low rate of virologic failure.
Youth activists living with HIV are speaking truth to power.
A new survey and educational campaign called “Owning HIV” offer insight.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
Merck’s experimental HIV drug proves effective and well tolerated
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.